Alkermes enters its July 27 earnings date with the short position meaningfully smaller than it was two weeks ago — a notable shift given that the prior note flagged shorts quietly rebuilding into the rally.
Short sellers have been covering steadily. SI dropped 6.2% over the past week to 10.3% of the float, after running as high as ~11.2% in early July. The retreat brings the borrowed position back toward its late-June levels, suggesting some tactical shorts added around the $40s have been squeezed out by the stock's 20% one-month gain to $52.72. The borrow market reflects little tension on either side: cost to borrow remains minimal at 0.46%, and availability is loose at 549% — meaning there are roughly five-and-a-half shares available for every one already borrowed. That's well above the 52-week low of 329%, consistent with a position that is unwinding rather than being squeezed. The ORTEX short score has also pulled back from 64.5 on July 7 to 61.1 today, tracking the reduction in net short pressure. Options positioning is similarly calm — the put/call ratio of 0.70 is barely above its 20-day average of 0.68, with a z-score near zero. Investors are not paying up for downside protection ahead of the print.
The Street's upgrade cycle has continued since the last note, though the consensus remains split. Needham raised its target a further dollar to $62 on July 13, staying at Buy. JP Morgan reinstated coverage the same day at Neutral with a $60 target — a signal that a bellwether firm sees fair value close to current levels but is not chasing the move. Mizuho and Wells Fargo, both at $65, represent the bull ceiling. Bank of America's Underperform at $38 — now roughly 28% below the current price — remains the outlier bear case. The mean target has moved to $51.59, which the stock has already cleared, a dynamic that has not resolved since early July. Bulls are anchored on the ALKS 2680 orexin agonist pipeline and the forthcoming alixorexton launch, citing the long-term extension data in narcolepsy types 1 and 2 as evidence of durable efficacy. Bears, led by BofA, see a limited sales force as a structural constraint and question whether the company can scale commercialization without significantly higher investment. The EPS surprise factor score ranks in the 99th percentile, suggesting the company has a strong track record of beating estimates — a relevant reference with results nine days out.
Institutional ownership offers a mild contrarian note. T. Rowe Price added 877,200 shares in the quarter to June 30, building to a 3.3% position. First Trust added over 1.5 million shares in the same period. BlackRock, the largest holder at 17% of shares, added a more modest 365,000. The insider picture tells a less encouraging story — the CMO sold 9,000 shares on July 1 at $51.46, adding to a string of executive sales across May and June. The 90-day net insider position is technically positive at $2.7 million, but that reflects awards rather than open-market purchases, and every disclosed cash transaction in the period has been a sale.
The last two earnings prints provide useful texture. In May 2026, the stock gained 3.4% on the day and 12.1% over the following five days — a strong post-earnings drift. The prior Q4 print produced a more muted response: down 0.5% on the day and 1.6% over five days. The Q2 2026 report on July 27 will be the first since the stock broke out materially above the analyst consensus, meaning the bar is higher and the gap between price and mean target offers less margin for disappointment than it did in May.
What to watch on July 27: whether management provides more granular commercialization guidance for alixorexton — specifically the sales force build-out timeline — will be the clearest test of the bear case; a second focus is any update on ALKS 4510 and ALKS 7290 that could either validate or challenge the pipeline premium now embedded in a stock trading at 35x earnings.
See the live data behind this article on ORTEX.
Open ALKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
